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ABSTRACT
There has been a signifi cant increase in research on probiotics-associated health benefi ts in the last 20 years. Many 
studies carried out in vitro and clinically show that consumption of probiotics inhibits the growth of pathogenic 
microorganisms. Furthermore, the consumption of probiotics also enhances the host immune response and decreases the 
levels of carcinogenesis-inducing enzymes. These positive outcomes have led to the use of probiotics in prevention and 
treatment of infectious diseases like bacterial or antibiotic associated diarrhea, chronic infl ammatory bowel diseases 
and colon cancer. This review summarises literature pertaining to mechanistic actions of probiotics in improving the 
well-being of hosts. 
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ABSTRAK
Terdapat peningkatan yang signifi kan dalam penyelidikan mengenai manfaat probiotik kepada kesihatan. Banyak kajian 
yang dijalankan secara in vitro dan klinikal menunjukkan bahawa pengambilan probiotik dapat merencat pertumbuhan 
mikroorganisma patogenik. Selain itu, pengambilan probiotik juga dapat meningkatkan tindak balas imun perumah 
dan mengurangkan tahap enzim yang terlibat dalam proses karsinogenesis. Hasil kajian yang positif ini menyebabkan 
probiotik digunakan dalam pencegahan dan rawatan penyakit seperti diarea yang disebabkan bakteria dan antibiotik, 
keradangan usus kronik dan kanser kolon. Ringkasan ini merumuskan kajian kesusasteraan yang berkaitan dengan 
mekanisme probiotik dalam meningkatkan kesihatan perumah.
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INTRODUCTION
The concept of probiotic was initially proposed by Elie 
Metchnikoff in 1910 who discovered that the relatively long 
life span of Bulgarians was due to daily intake of fermented 
dairy products (Bibel 1998). He believed that consumption 
of fermented milk products containing Lactobacillus 
contributed to the balance of microbial population in the 
colon. Since then, studies about probiotics continue to 
increase rapidly and a few defi nitions of probiotic have 
been proposed. Lilly & Stillwell (1965) defi ned probiotics 
as substances produced by microorganisms that promote 
growth of other microorganisms. Whereas Fuller (1989) 
described probiotics as food supplements consisting 
of live microorganisms that benefi t hosts by balancing 
microorganisms in the intestines. Later in 2001, FAO/WHO 
recommended the standard defi nition of probiotics which 
is “live microorganisms which are benefi cial to hosts when 
taken in suffi cient amounts”. 
The majority of probiotic bacteria are gram positive 
and they produce lactic acid. The genera of Lactobacillus 
and Bifidobacterium compose most of members of 
probiotic bacteria. Saccharomyces boulardii (S. boulardii), 
Saccharomyces cerevisiae (S. cerevisiae), Escherichia 
coli (E. coli) and Bacillus spp. are also included in some 
probiotic recipes (De Vrese & Schrezenmeir 2008). 
There are various mechanisms employed by probiotics 
in providing protection to the hosts. These mechanisms 
include inhibiting the growth of pathogenic microorganisms 
in the gastrointestinal tract, enhancing the host’s immune 
system, producing benefi cial enzymes and decreasing the 
level of enzymes involved in carcinogenesis. 
INHIBITION OF PATHOGENIC 
MICROORGANISMS
Probiotics prevent colonization of pathogenic 
microorganisms by producing antimicrobial peptides 
and compounds such as bacteriosin, organic acids and 
hydrogen peroxide. Production of organic acids by 
probiotic bacteria lowers the intestinal pH which then 
inhibits the growth of pathogenic microorganisms (Ng 
et al. 2009). For instance, Salmonella typhimurium 
(S. typhimurium) which causes Salmonellosis is unable 
to survive acidic conditions (Salminen & Wright 1998). 
Meanwhile, bacteriosin such as nisin is very effective in 
preventing the growth of gram-positive and gram-negative 
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pathogenic bacteria and yeast (Cleusix 2008). Nisin is made 
of cationic and hydrophobic domains. Both of the domains 
interact with bacterial membrane and subsequently 
disrupt the membrane integrity, thereby forming pores 
in the membrane. Pore formation causes outfl ow of ions 
(K+ and Mg2+), amino acids (glutamic acid, lysine) and 
ATP passively from the cytoplasm and eventually results 
in microbial cell death. Corr et al. (2007) showed that 
Lactobacillus salivarius protected mice from Listeria 
monocytogenes (L. monocytogenes) infection through the 
direct action of bacteriosin Abp118. In addition, sakacin 
produced by Lactobacillus sakei (L. sakei) 1 was also 
shown to inhibit the adherence of L. monocytogenes on 
stainless steel surface (Winkelströter et al. 2011). 
Probiotics also inhibit the growth of pathogens through 
competition for micronutrients and attachment site on 
the intestinal epithelia. Attachment of probiotics on the 
epithelial cell surface blocks the binding of pathogenic 
microorganisms (Kopp-Hoolihan 2001). In addition, 
probiotics are able to compete for micronutrients with 
pathogens, for example, competition for iron which is 
essential for the growth of bacteria. Hooper (2004) showed 
that L. acidophilus, L. delbrueckii and E. coli Nissle bound 
and chelated iron on the surface of the epithelial cells. This 
reduces the provision of iron to pathogens and eventually 
causes pathogen death.
The effectiveness of probiotics in inhibiting the growth 
of pathogenic bacteria has led to the use of probiotics in 
treating diarrhea and preventing pathogen infection in the 
intestine. For example, prevention of antibiotic associated 
diarrhea. Excessive intake of antibiotics disrupts the 
balance of microfl ora in the gastrointestine, thus allowing 
the emergence of resistant pathogenic bacteria such as 
Clostridium diffi cile (C. diffi cile) which causes diarrhea in 
humans. However, by consuming probiotics, the growth of 
C. diffi cile can be suppressed and the balance of intestinal 
microfl ora is then restored. A number of clinical studies 
demonstrated that ingestion of S. boulardii, Lactobacillus 
rhamnosus GG (L. rhamnosus GG), L. acidophilus, L. 
bulgaris reduced the occurrence of antibiotic associated 
diarrhea by as much as 52% (Sazawal et al. 2006). 
Helicobacter pylori (H. pylori) is commonly associated 
with chronic gastritis, peptic ulcers, and gastric cancer 
(Plummer et al. 2004). Apart from taking antibiotics and 
proton pump inhibitor as a treatment for H. pylori infection, 
probiotics have been employed in treating the bacterial 
infection. A number of animal studies showed that intake 
of L. casei Shirota reduced the colonization of H. pylori 
in the antrum and mucosa of the intestine (Sgouros et al. 
2004). In addition, Wang et al. (2004) also showed that 
intake of yogurt containing Bifi dobacterium animalis (B. 
animalis) Bb12 and L. acidophilus successfully suppressed 
H. pylori colonization and infection.
REDUCTION OF LACTOCE INTOLERANCE AND 
CARCINOGENESIS
Lack of β-galactosidase activity in the lower intestine 
causes lactose intolerance (Vasiljević & Shah 2012). 
Consumption of dairy products with high lactose content 
causes abdominal pain, diarrhea, nausea, and bloating 
in lactose intolerant individuals. The problems can 
be alleviated by consuming fermented dairy products 
supplemented with β-galactosidase producing Lactobacillus 
and Bifi dobacterium spp. (Montalto et al. 2005). A few in 
vivo studies in lactase-deficient subjects showed that 
consumption of probiotics reduced bloating symptoms 
and this was likely due to the presence of β-galactosidase 
produced by lactic acid bacteria (Hirayama & Rafter 2000 
for review, Gill & Guarner 2004).
Probiotics have been shown to decrease the activities 
of carcinogenic enzymes such as β-glucuronidase, 
azoreductase, and nitroreductase. According to Pedrosa et 
al. (1995), carcinogenic enzymes produced by intestinal 
microorganisms encourage the growth of cancers. Intake 
of probiotics not only inhibits the growth of harmful 
microfl ora but also reduces the levels of carcinogenic 
enzymes. Goldin (1996) showed that carcinogen-treated 
animals exhibited drastic tumor size reduction after being 
fed with L. rhamnosus GG. Furthermore, Salminen & 
Wright (1998) demonstrated that the levels of carcinogenic 
enzymes in human stool specimens were reduced 
signifi cantly following the intake of L. acidophilus and 
L. casei.
ANTIOXIDANT ENZYMES
Probiotic lactic acid bacteria have been shown to produce 
antioxidant enzymes such as glutathione-S-transferase 
(GST), glutathione (GSH) reductase and GSH peroxidase 
(Hayes et al. 2007). Antioxidant enzymes are essential in 
biotransformation of xenobiotic compounds, carcinogens, 
free radicals and peroxides that cause oxidative stress 
in cells. Increase in oxidative stress results in cirrhosis, 
atherosclerosis and cancers (Rice-Evans & Burdon 1993). 
Challa et al. (1997) reported a signifi cant increase in the 
GST level in rat colon following Bifi dobacterium longum 
feeding to the rats. In addition, Ejtahed et al. (2012) 
also showed that consumption of yogurt containing L. 
acidophilus La5 and Bifi dobacterium lactis Bb12 was 
capable of increasing the levels of erythrocyte superoxide 
dismutase and glutathione peroxidase activities in type II 
diabetic patients. In this light, probiotics are indeed able to 
improve anti-oxidative status in diabetic patients. 
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ENHANCEMENT OF HOST IMMUNE FUNCTION
Probiotics regulate host immune system by activating 
nuclear factor kappa beta (NF-κB), balancing T-helper cell 
response, stimulating the production of IgA, controlling 
infl ammatory reactions and increasing the activity of 
macrophages (Kalliomaki & Walker 2005). However, a 
balanced infl ammatory response is relatively important 
in order to avoid excessive intestinal infl ammation which 
leads to severe intestinal disorders such as infl ammatory 
bowel disease (IBD) and necrotizing enterocolitis (NEC).
Intestinal lymphoid tissues are stimulated by probiotic 
bacteria attachment to Toll-like receptors (TLRs) expressed 
on macrophages, dendritic cells, B cells and epithelial cells 
(Pasare & Medzhitov 2005). Such attachment induces the 
production of cytokines by immune cells and secretion 
of polymeric IgA by plasma cells (Kohler et al. 2003). 
Bacterial ligands on the surface of probiotic bacteria such 
as lipopolysaccharide (LPS) and lipoteichoic acid interact 
with TLR-2 and TLR-4 of dendritic cells and subsequently 
activate NF-κB which then migrates to the cell nucleus 
and binds to cytokine promoters. This binding then 
initiates infl ammatory cytokine mRNA transcription. Pro-
infl ammatory cytokines such as TNF-α (tumor necrosis 
factors), IL (interluekin)-1β, IL-8 and IL-6 are produced and 
subsequently involved in the activation of naïve T helper 
cells (Th0) into T helper (Th)1, Th2 and T-regulatory (Treg) 
cells (Momoko 2005). Th1 immune response is important 
in eliminating intracellular pathogens while Th2 response 
protects hosts against parasitic and extracellular pathogen 
infections (Delcenserie et al. 2008).
Probiotics also promote anti-infl ammatory responses 
during bacterial infection which helps to avoid excessive 
infl ammation in the intestine (Allan 2008). Interaction 
of CpG motifs in bacterial DNA with intracellular TLR-9 
in dendritic cells causes the generation of IL-4 and 
IL-6. These cytokines stimulate the activation of Th3 
cells (Rachmilewitz et al. 2004). The activated Th3 
cells secrete anti-infl ammatory cytokines such as IL-10 
and TGF-β to alleviate Th1-mediated pro-infl ammatory 
responses (Moore et al. 2001). The occurrence of Crohn’s 
disease and NEC is attributable to excessive Th1-mediated 
infl ammation. Several studies have shown that probiotics 
are able to suppress infl ammation in Crohn’s disease 
and NEC. Braat et al. (2004) reported a reduction in Th1 
cytokines such as TNF-α, IL-6 and IL-12 levels in Crohn’s 
patients given L. rhamnosus. Besides, a mixture of S. 
boulrdii and mesalamine was administered in patients 
suffering from Crohns’s disease (Guslandi et al. 2000). 
This recipe successfully helped to mitigate the severity 
of Crohns’s disease. The leading factor of NEC is mainly 
due to continuous and excessive infl ammation caused 
by pathogens or commensal bacteria in the distal small 
intestine in premature infants (Claud et al. 2004). Lin et al. 
(2005) showed that feeding of L. lactis and Bifi dobacteria 
infantum to premature infants for a few days after the birth 
palliated the occurrence of NEC. These results manifest 
the importance of probiotics in counterbalancing host’s 
pro- and anti-infl ammatory responses especially in patients 
suffering from intestinal disorders.
CONCLUSION
Consumption of probiotic has been shown to provide 
significant health benefits in preventing and treating 
intestinal infections and disorders and cancers. In view of 
this, it is worth noting that more studies and investigations 
are needed to uncover further health benefi ts of probiotics 
to humans.
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